Table 1.

Demographic, and main clinical and laboratory/instrumental findings of the subjects enrolled in this case series.

Patient	#1	#2	#3	#4	#5
Age, years	61	72	57	69	25
Sex	M	F	M	M	F
Diagnosis	Acute inflammatory demyelinating polyradiculoneuropathy (AIDP)	Acute inflammatory demyelinating polyradiculoneuropathy (AIDP)	Acute motor sensory axonal neuropathy (AMSAN)	Myelitis	Myelitis
Early symptoms of COVID-19	Cough, hyposmia and dysgeusia	Fever (up to 39°C), cough, ageusia	Fever (up to 39°C), cough and dysgeusia	Fever and asthenia	Fever (up to 38°C), anosmia and dysgeusia
Need for mechanical ventilation	Yes	No	No	No	No
COVID-19 treatment	None	Antibiotics, LMWH and hydroxychloroquine	None	Antibiotics, lopinavir/ritonavir, LMWH and hydroxychloroquine	LMWH
Latency of neurological symptoms, days	21	8	12	3	15
CSF findings	Normal, SARS-CoV-2 RT-qPCR negative	1st exam: normal, SARS-CoV-2 RT-qPCR negative 2nd exam: albumin-cytological dissociation	Normal, SARS-CoV-2 RT-qPCR negative	Marked pleocytosis with neutrophil prevalence, hyperproteinorrachia and oligoclonal bands, SARS-CoV-2 RT-qPCR negative	Normal (polyclonal distribution of immunoglobulins), SARS-CoV-2 RT-qPCR negative
Brain MRI findings	Not performed	Chronic cerebrovascular disease	Not performed	Normal	Normal
Spinal cord MRI findings	–	No signs of myelitis nor thickening or contrast enhancement of nerve roots	No signs of myelitis nor thickening or contrast enhancement of nerve roots	Multiple small T2-hyperintense cervical and thoracic lesions, mostly affecting the lateral and posterior columns	T2-hyperintensity at the thoracic spinal cord level mainly affecting the T3 and T8-T10 myelomeres
Neurological symptoms at baseline	Impaired walking and sensory loss at the lower limbs which rapidly evolved to tetraparesis with acute respiratory failure	Walking impairment and diffuse paresthesia, gradually evolving in a tetraparesis with sensory deficit in the four limbs	Progressive sensory-motor deficit in the four limbs (sensory symptoms prevalent on motor impairment)	Acute urinary retention, rapidly followed by complete motor and sensory impairment in the lower limbs	Hyposthenia in both legs, paresthesia and numbness with upper level at the breast line and sensation of incomplete bladder emptying
Acute Treatments of the neurological syndrome	IVIG, 1 cycle of 3 days (0.4 g/die)	IVIG, 2 cycles of 5 days each (0.4 g/die) within the first month	IVIG, 1 cycle of 5 days (0.4 g/die)	IVIG, 1 cycle of 5 days (0.4 g/die)	2 cycles of IV methylprednisolone 1 g/day (each of 7 days) with a 3-month interval
Chronic treatments of the neurological syndrome	None	Plasma exchange cycles, 6 times over 14 days	None	None	Low dose of oral prednisone with a tapering scheme over 2 months
Duration of rehabilitation treatment including physiotherapy and occupational therapy, days	120	179	36	128	72
Clinical outcome	Autonomy recovery; persistence of mild distal weakness at lower limbs	Autonomy in self transferring, ability to walk with aids and bilateral support	Autonomy recovery; walking with right ankle-foot orthosis	Autonomy recovery; normal walking but with early fatigue	Autonomy recovery; persistence of distal weakness at lower limbs and gait ataxia

IVIG, intravenous immunoglobulin; LMWH, low molecular weight heparin.